Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2025 | Long-term outcomes of PSA persistence after robotic prostatectomy

Alessandro Bertini • 28 Feb 2025
EAU 2025
Genitourinary Cancer Prostate Cancer

Alessandro Bertini, MD, IRCCS Ospedale San Raffaele, Milan, Italy & Henry Ford Health System, Detroit, MI, explores long-term survival and additional treatment rates in men with high-risk locally advanced prostate cancer and PSA persistence following robotic-assisted laparoscopic prostatectomy (RALP). Findings suggest that while PSA persistence increases the likelihood of requiring hormone therapy or radiotherapy, it does not significantly impact long-term cancer control outcomes. This interview took place at the 2025 European Association of Urology (EAU) Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alessandro Bertini

Perioperative outcomes of single- versus multi-port robotic prostatectomy
1:49
Perioperative outcomes of single- versus multi-port robotic prostatectomy
Alessandro Bertini • 28 Feb 2025
Assessing the incidence of bladder cancer during the COVID-19 pandemic
2:16
Assessing the incidence of bladder cancer during the COVID-19 pandemic
Alessandro Bertini • 28 Feb 2025
The impact of socioeconomic deprivation in oncological outcomes
2:23
The impact of socioeconomic deprivation in oncological outcomes
Alessandro Bertini • 28 Feb 2025
Socioeconomic disparities in quality of surgery in patients with MIBC
2:57
Socioeconomic disparities in quality of surgery in patients with MIBC
Alessandro Bertini • 28 Feb 2025

Related Videos

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals